AtriCure (ATRC) vs DENTSPLY SIRONA (XRAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AtriCure (ATRC) has outperformed DENTSPLY SIRONA (XRAY) over the past year, gaining 53.1% versus a loss of 21.6%. Over five years, ATRC leads with a -22.0% price change compared with -83.4% for XRAY. AtriCure is the larger company by market cap ($2.82 billion vs $1.65 billion), about 1.7 times the size.
On valuation, DENTSPLY SIRONA trades at a lower forward P/E (6.8x vs 122.1x for AtriCure). DENTSPLY SIRONA pays a dividend yielding 1.93%, while AtriCure does not currently pay one. AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -16.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | XRAY |
|---|---|---|
| Share price | $55.39 | $8.29 |
| Market cap | $2.82B | $1.65B |
| 1-day change | +2.37% | -2.36% |
| YTD return | +40.02% | -27.47% |
| 1-year return | +53.14% | -21.64% |
| 5-year return | -22.00% | -83.35% |
| P/E ratio (TTM) | 178.68 | — |
| Forward P/E | 122.12 | 6.78 |
| EPS (TTM) | $0.31 | $-0.61 |
| Dividend yield | 0.00% | 1.93% |
| Annual dividend | $0.00 | $0.16 |
| Revenue (latest FY) | $534.53M | $3.68B |
| Revenue growth (YoY) | +14.88% | -2.98% |
| Net income (latest FY) | $-11.45M | $-598.00M |
| Gross margin | 74.98% | 50.00% |
| Operating margin | -1.77% | -11.47% |
| Net margin | -2.14% | -16.25% |
| 52-week high | $66.02 | $14.76 |
| 52-week low | $25.36 | $8.14 |
| Distance from 52-week high | -16.10% | -43.83% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +17.15% | +29.92% |
| Average volume | 1.04M | 4.81M |
| Shares outstanding | 50.92M | 199.35M |
| Employees | 1,350 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed XRAY by 74.8 percentage points over the past year.
- DENTSPLY SIRONA offers a meaningfully higher dividend yield (1.93% vs 0.00%).
- AtriCure is more profitable, keeping -2.1 cents of every revenue dollar as net income versus -16.3 cents for DENTSPLY SIRONA.
- AtriCure grew revenue faster in its latest fiscal year (+14.88% vs -2.98%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About DENTSPLY SIRONA
XRAY stock →DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.
Health Care · Medical/Dental Instruments · 14,000 employees
ATRC vs XRAY FAQ
Which is bigger, AtriCure or DENTSPLY SIRONA?
AtriCure (ATRC) is larger, with a market capitalization of $2.82B compared with $1.65B for DENTSPLY SIRONA (XRAY).
Which stock has performed better over the past year, ATRC or XRAY?
ATRC returned +53.14% over the past 12 months, compared with -21.64% for XRAY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, AtriCure or DENTSPLY SIRONA?
DENTSPLY SIRONA pays a dividend yielding 1.93%, while AtriCure does not currently pay a regular dividend.
Are AtriCure and DENTSPLY SIRONA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.